Blue Jet Healthcare Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u9b5k7t0qe1gmkpwb8794m0y.pdf

Key Takeaways


PI Segment: The Quarter's Engine

VK Singh: "All that we are concerned with is the visibility that we have and our order book, which is all very robust. And we have a very good forecast for the future. In all 3 key markets, US, Europe and Japan. The molecule is getting some extremely good action and extremely good clinical reviews."

Contrast Media: Transit Noise Masks Steady Demand


Margins: Raw Material Pressure, Operating Leverage Offset

Ganesh Karuppannan: "Given the current geopolitical situation, raw material pricing trend will be uncertain in the period to come, and it will be difficult to forecast the impact in the current scenario."

Capex & Capacity: Three Projects in Motion

VK Singh: "What differentiates this investment is not merely the creation of additional capacity, but the flexibility of the platform. We are consciously designing Vizag to support multiple chemistry platforms, multiple customers and multiple product lifecycles..."

Pipeline & New Platforms: Diversification Beyond PI

Shiven Arora: "We will not be participating in the front-end generic peptide opportunity where you see cutter and a lot of price erosion."

ESG & Organizational Maturity

VK Singh: "It is like saying that the boy is not only smart, but he is a B. Tech engineer when you hire."

Guidance & Commitments

CommitmentSpecificsTimeline
PI intermediate revenue sustainabilityStrong order book and consistent production to sustain performanceThrough FY27
Contrast media goods-in-transit recognitionINR30-odd crores to be recognized as salesQ2 FY27
Iodinated contrast media intermediate commercial batchesPositive trend expectedEnd of Q2 FY27 or beginning of Q3 FY27
Contrast media segment launches3 candidates to launchFY27
Unit 3 (Mahad) backward integration commissioningSlightly ahead of H2 FY27 guidanceLater this calendar year
Hyderabad R&D center operationalCritical talent onboarded for Phase 1August 2026
Vizag Phase 1 capexINR1,000 crores over 3 years; FY27 spend ~INR250 croresFY27-FY30
Vizag Phase 1 commercializationAsset turn post-capitalization at industry normsEnd FY29 to FY30
Two high-conviction innovator programsAt least 2 opportunities to fructify'27/'28 timeframe
Lateral-entry chronic moleculesDefinitive comment promisedNext quarter
New high-intensity sweetenerPilot in existing facility; scale-up from Vizag; some revenue from existing facilityOngoing

Key Metrics

MetricQ1 FY27
Revenue from operations₹293 cr, up 25% QoQ
EBITDA₹98 cr
Gross margin53%, down 3% QoQ
Operating EBITDA margin33.5%, up 3% QoQ from 30.4% in Q4 FY26
Profit after tax margin26.7%, down 0.7% QoQ from 27.4% in Q4 FY26
Other operating income₹16.5 cr, driven by byproduct sales and export incentives; previously ₹2–3 cr per quarter
Goods in transit (unrecognized revenue)Higher by ₹30-odd cr vs opening cut-off; to be recognized in Q2 FY27
Contrast media plant utilization70-odd percent steady; production-to-dispatch at 100%
Contrast media revenue decline~40% QoQ (per an analyst's math)
PI-API segment order visibilityStrong order book, visibility for next 3–4 quarters
Unit 3 (Mahad) backward integration capex~₹210 cr invested; further ₹40 cr committed to complete this phase
Vizag Phase 1 investment~₹1,000 cr over the next 3 years
Total capex guidance (next 3 years)₹1,000-odd cr; FY27 spend expected at ~₹250 cr
Renewable energy share~70% of energy consumption from wind and solar
NCE programs with visibility4 programs in chronic therapy space progressing through customer development